Literature DB >> 11916954

Increased proinsulin levels and decreased acute insulin response independently predict the incidence of type 2 diabetes in the insulin resistance atherosclerosis study.

Anthony J G Hanley1, Ralph D'Agostino, Lynne E Wagenknecht, Mohammed F Saad, Peter J Savage, Richard Bergman, Steven M Haffner.   

Abstract

Previous studies have indicated that beta-cell dysfunction predicts the development of diabetes, although it is unknown whether the use of combinations of insulin secretory measures further improves prediction. The Insulin Resistance Atherosclerosis Study is a prospective, multicenter, epidemiological study of the relationship between insulin sensitivity and the risk of diabetes and cardiovascular disease. At baseline, fasting concentrations of insulin, intact proinsulin (PI), and split PI were measured, and acute insulin response (AIR) was determined during a frequently sampled intravenous glucose tolerance test (FSIGTT). Subjects who were nondiabetic at baseline (n = 903) were reexamined after 5 years of follow-up; 148 had developed diabetes. In separate logistic regression models adjusted for age, sex, clinic, and ethnicity, 1 SD differences in measures of beta-cell dysfunction were associated with diabetes incidence (AIR: odds ratio [OR] 0.37, 95% CI 0.27-0.52; intact PI: OR 1.90, 95% CI 1.57-2.30; split PI: OR 1.94, 95% CI 1.63-2.31). After additional adjustment for BMI, impaired glucose tolerance, and insulin sensitivity, these measures continued to be significantly associated with risk of diabetes (all P < 0.0001). Furthermore, in models that included both PI and AIR, each was an independent predictor, and individuals who had combined low AIR and high PI experienced the highest diabetes risk. In conclusion, both low AIR and high PI independently predicted diabetes in a well-characterized multiethnic population. Although fasting PI is simpler to assess, determining AIR from an FSIGTT may further improve prediction. If pharmacological agents to prevent diabetes are proved to be efficacious in ongoing clinical trials, then it may be beneficial to perform FSIGTTs to identify better (for intensive intervention) prediabetic subjects who would ultimately require lifelong pharmacological therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11916954     DOI: 10.2337/diabetes.51.4.1263

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  34 in total

1.  Proinsulin-to-C-peptide ratio versus proinsulin-to-insulin ratio in the prediction of incident diabetes: the Insulin Resistance Atherosclerosis Study (IRAS).

Authors:  R C Loopstra-Masters; S M Haffner; C Lorenzo; L E Wagenknecht; A J Hanley
Journal:  Diabetologia       Date:  2011-09-30       Impact factor: 10.122

2.  Characterisation of subjects with early abnormalities of glucose tolerance in the Stockholm Diabetes Prevention Programme: the impact of sex and type 2 diabetes heredity.

Authors:  J Kuhl; A Hilding; C G Ostenson; V Grill; S Efendic; P Båvenholm
Journal:  Diabetologia       Date:  2004-12-24       Impact factor: 10.122

3.  Detailed physiologic characterization reveals diverse mechanisms for novel genetic Loci regulating glucose and insulin metabolism in humans.

Authors:  Erik Ingelsson; Claudia Langenberg; Marie-France Hivert; Inga Prokopenko; Valeriya Lyssenko; Josée Dupuis; Reedik Mägi; Stephen Sharp; Anne U Jackson; Themistocles L Assimes; Peter Shrader; Joshua W Knowles; Björn Zethelius; Fahim A Abbasi; Richard N Bergman; Antje Bergmann; Christian Berne; Michael Boehnke; Lori L Bonnycastle; Stefan R Bornstein; Thomas A Buchanan; Suzannah J Bumpstead; Yvonne Böttcher; Peter Chines; Francis S Collins; Cyrus C Cooper; Elaine M Dennison; Michael R Erdos; Ele Ferrannini; Caroline S Fox; Jürgen Graessler; Ke Hao; Bo Isomaa; Karen A Jameson; Peter Kovacs; Johanna Kuusisto; Markku Laakso; Claes Ladenvall; Karen L Mohlke; Mario A Morken; Narisu Narisu; David M Nathan; Laura Pascoe; Felicity Payne; John R Petrie; Avan A Sayer; Peter E H Schwarz; Laura J Scott; Heather M Stringham; Michael Stumvoll; Amy J Swift; Ann-Christine Syvänen; Tiinamaija Tuomi; Jaakko Tuomilehto; Anke Tönjes; Timo T Valle; Gordon H Williams; Lars Lind; Inês Barroso; Thomas Quertermous; Mark Walker; Nicholas J Wareham; James B Meigs; Mark I McCarthy; Leif Groop; Richard M Watanabe; Jose C Florez
Journal:  Diabetes       Date:  2010-02-25       Impact factor: 9.461

4.  Disease risk factors identified through shared genetic architecture and electronic medical records.

Authors:  Li Li; David J Ruau; Chirag J Patel; Susan C Weber; Rong Chen; Nicholas P Tatonetti; Joel T Dudley; Atul J Butte
Journal:  Sci Transl Med       Date:  2014-04-30       Impact factor: 17.956

5.  Non-alcoholic fatty liver disease and impaired proinsulin conversion as newly identified predictors of the long-term non-response to a lifestyle intervention for diabetes prevention: results from the TULIP study.

Authors:  Vera Schmid; Robert Wagner; Corinna Sailer; Louise Fritsche; Konstantinos Kantartzis; Andreas Peter; Martin Heni; Hans-Ulrich Häring; Norbert Stefan; Andreas Fritsche
Journal:  Diabetologia       Date:  2017-08-24       Impact factor: 10.122

6.  Long-term effect of metformin on metabolic parameters in the polycystic ovary syndrome.

Authors:  Kai I Cheang; Jessica M Huszar; Al M Best; Susmeeta Sharma; Paulina A Essah; John E Nestler
Journal:  Diab Vasc Dis Res       Date:  2009-04       Impact factor: 3.291

7.  Beta cell dysfunction in patients with acute myocardial infarction but without previously known type 2 diabetes: a report from the GAMI study.

Authors:  M Wallander; M Bartnik; S Efendic; A Hamsten; K Malmberg; J Ohrvik; L Rydén; A Silveira; A Norhammar
Journal:  Diabetologia       Date:  2005-09-06       Impact factor: 10.122

8.  A common variant upstream of the PAX6 gene influences islet function in man.

Authors:  E Ahlqvist; F Turrini; S T Lang; J Taneera; Y Zhou; P Almgren; O Hansson; B Isomaa; T Tuomi; K Eriksson; J G Eriksson; V Lyssenko; L Groop
Journal:  Diabetologia       Date:  2011-09-16       Impact factor: 10.122

9.  Risk factors for type 2 diabetes mellitus preceded by β-cell dysfunction, insulin resistance, or both in older adults: the Cardiovascular Health Study.

Authors:  Fumiaki Imamura; Kenneth J Mukamal; James B Meigs; José A Luchsinger; Joachim H Ix; David S Siscovick; Dariush Mozaffarian
Journal:  Am J Epidemiol       Date:  2013-05-24       Impact factor: 4.897

10.  Effect of Rosiglitazone and Ramipril on {beta}-cell function in people with impaired glucose tolerance or impaired fasting glucose: the DREAM trial.

Authors:  Anthony J Hanley; Bernard Zinman; Patrick Sheridan; Salim Yusuf; Hertzel C Gerstein
Journal:  Diabetes Care       Date:  2009-12-15       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.